Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD)
Closed Pre-Solicitation Posted
- Solicitation number
- 25-007587
- Agency
-
NIH Clinical Center
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Bethesda, Maryland 20892, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health Clinical Center, through its Critical Care Medicine Department, intends to sole source specialized genomics reagents from 10X Genomics, Inc. located in Pleasanton, California. The procurement involves four specific 10X Genomics kits including Dual Index TS Set A, GEM-X Flex Sample Preparation v2 Kit, GEM-X Flex Gene Expression Chip Kit, and GEM-X Flex Gene Expression Human samples, all required for a research project investigating SARS-CoV-2's impact on human brain tissues and cerebral organoid tissues at the single-cell level. The agency emphasizes that these proprietary kits contain specialized reagents for RNA isolation and amplification using unique barcoding technology, and that the department has already validated protocols for BSL-3 compliance with these specific products. No substitutions are acceptable as any changes would require up to one year of re-validation, potentially impacting patient care and research continuity. Interested parties capable of providing similar products may submit capability statements by June 21, 2025, at 3:00 PM EST to Contract Specialist Tasha Lowe.
This procurement does not utilize any set-aside designations and will be conducted under FAR Part 13 Simplified Acquisition Procedures, which allows for single-source solicitation when only one source is reasonably available. The specific quantities required include one each of the Dual Index Kit, Sample Preparation Kit, and Gene Expression Chip Kit, plus four units of the Gene Expression Human samples. The contract will be structured as a firm fixed-price purchase order, though no specific dollar values are disclosed in the notice. The procurement is being justified on the basis that 10X Genomics is the sole manufacturer of the required platform and single-cell sequencing reagents, making this a proprietary acquisition. The acquisition falls under the simplified acquisition threshold, exempting it from standard competition requirements under FAR Part 6.
Notice text
Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD)
- Product Service Code: 6550
- NAICS Code: 325413
- Place of Performance:
Bethesda, MD 20892
POTS: 25-007587
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH), Office of Purchasing and Contracts on behalf of the Critical Care Medicine Department (CCMD) intends to award a firm fixed price Purchase Order to 10X Genomics, Inc, located in Pleasanton, California 94588-3260 on a sole source basis to provide 10X Genomics reagents.
The Critical Care Medicine Department is currently working on a project investigating the impact of SARS-CoV-2 infection on human brain tissues and cerebral organoid tissues at the single-cell level. The study utilizes 10X Genomics Dual Index TS Set A 96 rxn Kits, GEM-X Flex Sample Preparation v2 Kits, GEM-X Flex Gene Expression Chip, 4 chips kits, and GEM-X Flex Gene Expression Human 4 samples. These proprietary kits contain specialized reagents designed for the isolation and amplification of uniquely barcoded ribonucleic acid (RNA). The 10X Genomics platform uses microfluidics to separate individual cells into an emulsion with single gel beads and labels the RNA from each cell with a unique barcode for partitioning into libraries for sequencing.
The Critical Care Medicine Department has independently modified and validated the recommended protocols provided by 10X Genomics to be compliant with “Biosafety Level 3” (BSL-3 requirements). There are no substitutions of equipment or reagents for this study and used under the existing protocols. Any change of equipment or reagents would cause a stoppage of work, and the substitutions would have to undergo a re-validation process that could take up to one year or more. This ultimately would negatively impact patient care by causing a delay and stoppage of work that would impact patient care and the research process. 10X Genomics, Inc kits are proprietary and are the only approved kits to be used in this research project. 10X Genomics is the sole manufacturer of the platform and single cell sequencing reagents.
The below items are required for this action:
Description/Product Code/Quantity:
Dual Index Kit TS Set A, 96 rxn / Product Code: 1000251 / QTY: 1
GEM-X Flex Sample Preparation v2 Kit / Product Code: 1000781 / QTY: 1
GEM-X Flex Gene Expression Chip Kit, 4 chips / Product Code: 1000791 / QTY: 1
GEM-X Flex Gene Expression Human, 4 samples / Product Code: 1000792 / QTY: 4
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Interested Parties:
Interested parties capable of providing the same or similar products or services described in this notice may submit a capability statement outlining their capability to perform the described work. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. The determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Comments:
Comments to this announcement, referencing this posting number on the email subject line, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Tasha Lowe Contract Specialist, lowet2@mail.nih.gov by the due date June 21, 2025, (3:00 pm EST) and time marked in this notice.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity